6-[[2-(二甲基氨基)乙基]氨基]-3-羟基-7H-茚并[2,1-C]喹啉-7-酮二盐酸盐 | 174634-09-4

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-[[2-(二甲基氨基)乙基]氨基]-3-羟基-7H-茚并[2,1-C]喹啉-7-酮二盐酸盐
• 中文别名: 6-[[2-(二甲基氨基)乙基]氨基]-3-羟基-7H-茚并[2,1-c]喹啉-7-酮二盐酸盐；6-[2-(二甲氨基)乙胺基]-3-羟基-7H-茚并[2,1-c]喹啉-7-酮二盐酸；TAS-103二盐酸盐
• 英文名称: Tas-103
• 英文别名: 6-[2-(dimethylamino)ethylamino]-3-hydroxyindeno[2,1-c]quinolin-7-one;dihydrochloride
• CAS: 174634-09-4
• 化学式: C20H21Cl2N3O2
• 分子量: 406.3
• InChiKey: HAYAYGFVSIWSGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.97
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  65.5
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  6-(((dimethylamino)ethyl)amino)-3-methoxy-7H-indeno[2,1-c]quinoline-7-on 以65.3的产率得到6-[[2-(二甲基氨基)乙基]氨基]-3-羟基-7H-茚并[2,1-C]喹啉-7-酮二盐酸盐
  参考文献：
  名称：

  Condensed-indan derivatives and pharmaceutically acceptable salts thereof

  摘要：

  一种由式（1）表示的紧缩印度衍生物及其药学上可接受的盐：##STR1## 其中环A代表可选取代的萘环，环B代表可选取代的苯环或具有较低的烷基二氧基基团的苯环。Y代表--N.dbd.CR--或--CR.dbd.N--，R代表--NR.sub.1 R.sub.2基团，可选取代的含氮杂环基团或--OR.sub.3基团，其中R.sub.1和R.sub.2相同或不同，每个都是氢原子;苯基;可选取代的含氮杂环基团;或可由选自选组中的至少一种取代的低烷基基团，所述选组由可选取代的氨基基团，低烷氧基，苯基，含氮杂环基团，被低烷基取代的胺氧基团或羟基（s）组成;R.sub.3代表可选取代的被取代氨基基团取代的低烷基基团。

  公开号：

  US05710162A1

文献信息

• Topoisomerase inhibitors for prevention of restenosis
  申请人：Quanam Medical Corporation

  公开号：US20020004679A1

  公开（公告）日：2002-01-10

  A method of inhibitng cellular proliferation associated with a hyperproliferative condition, such as restenosis, is described. The method includes administering a topoisomerase inhibitor. A stent for local administration of the topoisomerase inhibitor is also described.

  本文描述了一种抑制细胞增殖的方法，该方法与细胞增殖亢进症（如再狭窄）有关。该方法包括施用拓扑异构酶抑制剂。还描述了一种用于局部施用拓扑异构酶抑制剂的支架。
• Liposome-entrapped topoisomerase inhibitors
  申请人：Alza Corporation

  公开号：US20020146450A1

  公开（公告）日：2002-10-10

  A composition for administration of a therapeutically effective dose of a topoisomerase inhibitor I or topoisomerase I/II inhibitor is described. The composition includes liposomes having an outer surface and an inner surface defining an aqueous liposome compartment, and being composed of a vesicle-forming lipid and of a vesicle-forming lipid derivatized with a hydrophilic polymer to form a coating of hydrophilic polymer chains on both the inner and outer surfaces of the liposomes. Entrapped in the liposomes is the topoisomerase inhibitor at a concentration of at least about 0.10 &mgr;mole drug per &mgr;mole lipid.

  本文描述了一种用于给药治疗有效剂量的拓扑异构酶抑制剂 I 或拓扑异构酶 I/II 抑制剂的组合物。该组合物包括具有外表面和内表面的脂质体，外表面和内表面限定了一个水性脂质体区室，脂质体由囊泡形成脂质和用亲水性聚合物衍生物化的囊泡形成脂质组成，以在脂质体的内外表面形成亲水性聚合物链涂层。脂质体中包裹的拓扑异构酶抑制剂的浓度至少为每摩尔脂质0.10摩尔药物。
• Methods for detection of promoter polymorphism in a UGT gene promoter
  申请人：Arch Development Corporation

  公开号：US20020115097A1

  公开（公告）日：2002-08-22

  The present invention is directed to methods for detecting the presence of genetic polymorphisms that correlate with altered gene expression. More specifically, the present invention is directed to methods for detecting the genetic polymorphisms located in the UGT1A1 promoter. The invention also provides methods for optimizing drug dosages based upon the presence of the polymorphisms. The invention further provides methods of predicting sensitivity to xenobiotics and diagnostic kits for detecting genetic polymorphisms.

  本发明涉及检测与基因表达改变相关的基因多态性存在的方法。更具体地说，本发明涉及检测位于 UGT1A1 启动子中的遗传多态性的方法。本发明还提供了根据多态性的存在优化药物剂量的方法。本发明进一步提供了预测对异种生物敏感性的方法和检测基因多态性的诊断试剂盒。
• Optimization of cancer treatment with irinotecan
  申请人：The University of Chicago

  公开号：US20040203034A1

  公开（公告）日：2004-10-14

  Various embodiments of the invention include methods and compositions for evaluating the risk of irinotecan toxicity in a patient. In certain embodiments, the methods include detecting a promoter polymorphism in one or both UGT1A1 genes of the patient. In particular embodiments the promoter polymorphism is a single nucleotide polymorphism and may be in linkage disequilibrium with a UGT1A1 (TA) n repeat. The methods may include obtaining a nucleic acid sample from the patient and detecting the presence or absence of a promoter polymorphism. The promoter polymorphism may be at nucleotide position −3440, −3401, −3279, −3177, −3175, or −3156 from the UGT1A1 gene transcriptional start site. The number of TA repeats can be 5, 6, 7, 8 more TA repeats. In particular embodiments, the promoter polymorphism is a −3440C>A, −3401T>C, −3279G>T, −3177C>G, −3175A>G, −3156G>A polymorphism or any combination thereof. Moreover, in other embodiments, identification of a guanine residue at position −3156 indicates the patient does not have a low level of UGT1A1 activity, and therefore, methods and compositions of the invention concern this identification.

  本发明的各种实施方案包括用于评估患者伊立替康毒性风险的方法和组合物。在某些实施方案中，这些方法包括检测患者一个或两个 UGT1A1 基因中的启动子多态性。在特定的实施方案中，启动子多态性是单核苷酸多态性，可与 UGT1A1 (TA) n 重复。这些方法可包括从患者处获取核酸样本并检测启动子多态性的存在与否。启动子多态性可位于 UGT1A1 基因转录起始位点的核苷酸位置-3440、-3401、-3279、-3177、-3175 或 -3156。TA重复序列的数量可以是5、6、7、8个TA重复序列。在特定的实施方案中，启动子多态性是-3440C>A、-3401T>C、-3279G>T、-3177C>G、-3175A>G、-3156G>A多态性或它们的任意组合。此外，在其他实施方案中，鉴定出-3156位的鸟嘌呤残基表明患者的UGT1A1活性水平不低，因此，本发明的方法和组合物与此鉴定有关。
• TOPOISOMERASE INHIBITORS FOR PREVENTION OF RESTENOSIS
  申请人：Quanam Medical Corporation

  公开号：EP1087801A1

  公开（公告）日：2001-04-04